Full-Life Technologies Limited

A recent conference in China spotlighted trends around diversification of bioconjugates, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) seen leading the novel

South Korea's SK Biopharmaceuticals Co., Ltd is looking to continue its growth story via a new diversification into the globally hot area of radiopharmaceuticals through a licensing agreement with C

Biotech financing deals in China, backed by venture capital and private equity firms, started to pick up in January and deal sizes also crossed the CNY200m ($28m) mark. Apart from Ji Xing Pharmaceuti

In a sure sign that the annual J.P. Morgan Healthcare Conference in San Francisco will soon be under way, the waning days of December and the first week of January brought a deluge of new funding anno